Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate selective depletion of naïve CD45RA+ T cells from allogenic peripheral blood stem cell graft in children transplanted for combined immune deficiency. The aims of this procedure are to prevent graft versus host disease (GVHD) while preserving anti-infectious response from donor memory T lymphocytes.

Detailed Description
-----------------
Combined immunodeficiencies (CIDs) are an heterogeneous group of primitive immunodeficiency (PID), which affect T cells development, function or both. These inherited conditions can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). These procedures have a high risk of morbidity and mortality such a graft versus host disease (GVHD), rejection of the graft and serious infections, especially in this population of children with PID. GVHD is more frequent and severe if the donor is not an identical sibling and/or presents an HLA-mismatch. GVHD requires high immunosuppression as prevention and treatment, and therefore impedes immunity against infections. In vitro and animal models suggest that GVHD is mediated by naïve T cells. The aim of this study is to decrease the rate and severity of GVHD after selective depletion of naïve CD45RA+ T cells from allogeneic hematopoietic stem cell grafts in patients with CIDs with high risk of severe GVHD, and to preserve immunity against pathogens in a population with high vulnerability to infections. The project aims is, first, to show improvement of rejection-free and GVH-free survival 12 months post-transplant, and secondly, to show the decrease of viral infection, and assess immune reconstitution kinetic and quality and specific antiviral responses, after a engraftment with naïve cell depleted allograft.

Official Title
-----------------
Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID): Selective Depletion of Naive Cells From the Graft

Conditions
-----------------
Combined Immunodeficiencies

Intervention / Treatment
-----------------
* Biological: Depletion in CD45RA graft donor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient from 12 months to 18 years Combined immunodeficiencies with known molecular diagnosis or if unknown, corresponding of p-CID study's definition Hematopoietic stem cell Transplantation planned with one of the following donors : sibling with 1 or 2 HLA antigens mismatch parent 10/10 or 9/10 identical unrelated donor: 10/10 or 9/10 identical Consent form signed by the child's legal guardian Patient using effectiveness contraception during this trial Affiliated or beneficiary of a health insurance regimen Exclusion Criteria: Wiskott-Aldrich syndrome Ongoing pregnancy Positive HIV PCR Contraindication for hematopoetic stem cell transplantation Geno-identical donor in the siblings hematopoetic stem cell transplantation antecedent

Ages Eligible for Study
-----------------
Minimum Age: 12 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br> | Biological: Depletion in CD45RA graft donor<br>* Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product. Conditioning regimen: Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2 Graft: CD34+ cells positively selected cells from PBSC of the donor Post transplant immunosuppression: ciclosporin started at D-1 to D+100<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of death |  | 12 months after the transplantation | 
| Number of graft rejection |  | 12 months after the transplantation | 
| Number of graft versus host disease (GVHD) grade III or IV |  | 12 months after the transplantation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Need of antiviral treatment | to assess viral infection | 12 months after the transplantation | 
| T Lymphocyte proliferations to phytohemagglutinin (PHA) | to assess immune reconstitution | 12 months after the transplantation | 
| Proportion of T CD4 and CD8 lymphocytes specific of cytomegalovirus, Epstein Barr virus and adenovirus | to assess specific antiviral response | 12 months after the transplantation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CD45RA, Combined immunodeficiencies, hematopoietic stem cell transplantation, primitive immunodeficiencies, pediatric transplantation, CD45RA depletion